Cancer Statistics, 2002

Every year the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival, using National Cancer Institute (NCI) incidence and National Center for Health Statistics (NCHS) mortality data. Incidence and death rates are age adjusted to the 1970 US standard population. It is estimated that 1,284,900 new cases of cancer will be diagnosed and 555,500 people will die from cancer in the United States in the year 2002. From 1992 to 1998, cancer death rates declined in males and females, while cancer incidence rates decreased among males and increased slightly among females. Most notably, African‐American men showed the largest decline for both incidence and mortality. Nevertheless, African Americans still carry the highest burden of cancer with later‐stage cancer diagnosis and poorer survival compared with whites. Despite the continued decline in cancer death rates, the total number of recorded cancer deaths in the United States continues to increase slightly due to the aging and expanding population.

[1]  B. Schneider.  MANUAL of the international statistical classification of diseases, injuries, and causes of death. Addendum 1. Supplementary interpretations and instructions for coding causes of death. , 1953, Bulletin of the World Health Organization. Supplement.

[2]  H M Rosenberg,et al.  Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. , 2001, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[3]  S. P. Fodor,et al.  Strategies for mutational analysis of the large multiexon ATM gene using high-density oligonucleotide arrays. , 1998, Genome research.

[4]  Jean-Charles Sanchez,et al.  Proteomics: new perspectives, new biomedical opportunities , 2000, The Lancet.

[5]  U. Alon,et al.  Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. , 2001, Cancer research.

[6]  T. Aitman,et al.  DNA microarrays in medical practice , 2001, BMJ : British Medical Journal.

[7]  D. Lashkari,et al.  High-throughput genomic and proteomic analysis using microarray technology. , 2001, Clinical chemistry.

[8]  K. Furge,et al.  Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Bittner,et al.  Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. , 2001, Cancer research.

[10]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[11]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[12]  H M Rosenberg,et al.  Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. , 2001, Journal of the National Cancer Institute.

[13]  P. Brown,et al.  Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  E. Dougherty,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[16]  James L. Winkler,et al.  Accessing Genetic Information with High-Density DNA Arrays , 1996, Science.

[17]  G Rennert,et al.  Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. , 2001, The American journal of pathology.

[18]  Jeffrey A. Magee,et al.  Expression profiling reveals hepsin overexpression in prostate cancer. , 2001, Cancer research.

[19]  H. Dorn,et al.  Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death. Vol. I , 1950 .

[20]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[21]  P. Wingo,et al.  An adjustment to the 1997 estimate for new prostate cancer cases , 1997, CA: a cancer journal for clinicians.

[22]  Daniel H. Geschwind,et al.  Sharing gene expression data: an array of options , 2001, Nature Reviews Neuroscience.

[23]  C. Cooper,et al.  Applications of microarray technology in breast cancer research , 2001, Breast Cancer Research.

[24]  M. White,et al.  Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. , 2000, Cancer research.

[25]  Zhihua Liu,et al.  Gene expression profile changes in initiation and progression of squamous cell carcinoma of esophagus , 2001, International journal of cancer.

[26]  Petricoin Ef rd,et al.  Cancer proteomics: from biomarker discovery to signal pathway profiling. , 2001, Cancer journal.

[27]  O. Kallioniemi,et al.  Tissue microarrays (TMAs) for high‐throughput molecular pathology research , 2001, International journal of cancer.

[28]  S. P. Fodor,et al.  Light-generated oligonucleotide arrays for rapid DNA sequence analysis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. P. Fodor,et al.  Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two–colour fluorescence analysis , 1996, Nature Genetics.

[30]  D A Rew,et al.  DNA microarray technology in cancer research. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[31]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[33]  L. Bubendorf.  High–Throughput Microarray Technologies: From Genomics to Clinics , 2001, European Urology.

[34]  M. Chicurel.  Faster, better, cheaper genotyping , 2001, Nature.

[35]  S. Maxwell,et al.  Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  U. Certa,et al.  Expression profiling of glucocorticoid-treated T-ALL cell lines: rapid repression of multiple genes involved in RNA-, protein- and nucleotide synthesis , 2001, Oncogene.

[38]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 1999, Journal of the National Cancer Institute.

[39]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[40]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[41]  Axel Hoos,et al.  Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations , 2001, Laboratory Investigation.

[42]  S Hanash,et al.  Proteomics in early detection of cancer. , 2001, Clinical chemistry.